Daewoong Pharma reports 104 patients enrolled in Phase 2 IPF trial of Bersiporocin

Bitget2026/09/24 07:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Daewoong Pharma presented baseline data for 104 patients in a global Phase 2 trial of IPF candidate bersiporocin at ERS 2026.
The study is designed to test the drug in patients already on standard antifibrotic therapy, as well as those not receiving it.
Enrollment is complete in the US and South Korea, positioning the program for a key efficacy and safety readout.
Top-line Phase 2 results are expected in H1 2027, a near-term catalyst for the asset’s next-stage development plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daewoong Pharma published the original content used to generate this news brief via PR Newswire (Ref. ID: EN54703) on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Daewoong Pharma reports 104 patients enrolled in Phase 2 IPF trial of Bersiporocin

You may also like

Crypto prices